Literature DB >> 9737386

Experience with the Vero cell line.

B J Montagnon1, J C Vincent-Falquet.   

Abstract

The Vero cell line has been managed with the Cell Bank system to produce at the 142nd passage IPV, OPV and rabies vaccines since 1982 by Pasteur Mérieux Serums & Vaccins (PMsv). The safety of the cell line was regularly validated at the Working Cell Bank (WCB) level according to the WHO and European Pharmacopoeia requirements for absence of bacteria, fungi, mycoplasma and viruses. A special emphasis was devoted to research on the absence of simian viruses (SV40, SIV, Retro-D virus and simian CMV). All these specific researches were negative. At a low level of passage, the Vero cells are not tumorigenic. Vaccines have been prepared in low passage level Vero cells and together with the excellent downstream purification have resulted in excellent safety as attested by pharmacovigilance of more than 100 million doses of IPV during 12 years, more than 20 million doses of rabies vaccine during 10 years and more than 1 billion of OPV during eight years.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9737386

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  7 in total

Review 1.  Product review on the JE vaccine IXIARO.

Authors:  Christa Firbas; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.

Authors:  T Tao; M H Skiadopoulos; F Davoodi; J M Riggs; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

3.  A serum-free Vero production platform for a chimeric virus vaccine candidate.

Authors:  Inn H Yuk; Gina B Lin; Hui Ju; Inesse Sifi; Yvonne Lam; Armida Cortez; Danny Liebertz; J Michael Berry; Richard M Schwartz
Journal:  Cytotechnology       Date:  2006-11-16       Impact factor: 2.058

4.  Poliovirus-nonsusceptible Vero cell line for the World Health Organization global action plan.

Authors:  Yuko Okemoto-Nakamura; Kenji Someya; Toshiyuki Yamaji; Kyoko Saito; Makoto Takeda; Kentaro Hanada
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

5.  Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2.

Authors:  Martin Michaelis; Malte C Kleinschmidt; Denisa Bojkova; Holger F Rabenau; Mark N Wass; Jindrich Cinatl
Journal:  Front Microbiol       Date:  2019-12-03       Impact factor: 5.640

Review 6.  Matrix and backstage: cellular substrates for viral vaccines.

Authors:  Ingo Jordan; Volker Sandig
Journal:  Viruses       Date:  2014-04-11       Impact factor: 5.048

7.  Novel endogenous simian retroviral integrations in Vero cells: implications for quality control of a human vaccine cell substrate.

Authors:  Chisato Sakuma; Tsuyoshi Sekizuka; Makoto Kuroda; Fumio Kasai; Kyoko Saito; Masaki Ikeda; Toshiyuki Yamaji; Naoki Osada; Kentaro Hanada
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.